Literature DB >> 20145007

Low-valency, but not monovalent, antigens trigger the B-cell antigen receptor (BCR).

Susana Minguet1, Elaine-Pashupati Dopfer, Wolfgang W A Schamel.   

Abstract

Antigen binding to the B-cell antigen receptor (BCR) leads to receptor triggering and B-lymphocyte activation. Here, we have probed the molecular requirements for BCR triggering in primary murine B cells using a set of defined soluble haptenated peptides. Bi- and trivalent haptens activated the BCR, as measured by protein phosphorylation, Ca(2+) influx, BCR down-modulation and CD69, CD86 and MHC class II up-regulation. In contrast, four distinct monovalent haptens were ineffective. Next, we used two different anti-idiotypic antibodies, which bind to the antigen-combining site of the BCR. Again, monovalent Fab fragments were ineffective, whereas bivalent antibodies could stimulate the BCR. These findings are compatible with ligand-induced clustering of monomeric BCRs or re-organization of BCR complexes within pre-formed BCR oligomers. Lastly, an increase in the valency of the haptenated peptides improved the activation potential, whereas variations in the distance between two haptens had no effect. This finding contributes to understand how the immune system can efficiently recognize structurally diverse antigens but still discriminate between foreign and self.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20145007     DOI: 10.1093/intimm/dxp129

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  23 in total

1.  Protein sorting by lipid phase-like domains supports emergent signaling function in B lymphocyte plasma membranes.

Authors:  Matthew B Stone; Sarah A Shelby; Marcos F Núñez; Kathleen Wisser; Sarah L Veatch
Journal:  Elife       Date:  2017-02-01       Impact factor: 8.140

2.  Flow Cytometric and Cytokine ELISpot Approaches To Characterize the Cell-Mediated Immune Response in Ferrets following Influenza Virus Infection.

Authors:  Anthony DiPiazza; Katherine Richards; Frances Batarse; Laura Lockard; Hui Zeng; Adolfo García-Sastre; Randy A Albrecht; Andrea J Sant
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

3.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

4.  Anti-non-Gal-specific combination treatment with an anti-idiotypic Ab and an inhibitory small molecule mitigates the xenoantibody response.

Authors:  John M Stewart; Alice F Tarantal; Yan Chen; Nancy C Appleby; Tania I Fuentes; C Chang I Lee; Evelyn J Salvaris; Anthony J F d'Apice; Peter J Cowan; Mary Kearns-Jonker
Journal:  Xenotransplantation       Date:  2014-03-17       Impact factor: 3.907

5.  Monte Carlo study of B-cell receptor clustering mediated by antigen crosslinking and directed transport.

Authors:  A Srinivas Reddy; Philippos K Tsourkas; Subhadip Raychaudhuri
Journal:  Cell Mol Immunol       Date:  2011-02-28       Impact factor: 11.530

Review 6.  Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines.

Authors:  Hunter McFall-Boegeman; Xuefei Huang
Journal:  Expert Rev Vaccines       Date:  2022-01-24       Impact factor: 5.217

7.  A novel synthetic bipartite carrier protein for developing glycotope-based vaccines.

Authors:  Hsiao-Ling Chiang; Chi-Yu Lin; Fan-Dan Jan; Yaoh-Shiang Lin; Chia-Tse Hsu; Jacqueline Whang-Peng; Leroy F Liu; Shin Nieh; Chun-Cheng Lin; Jaulang Hwang
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

8.  TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate.

Authors:  Jingya Xia; Evandro R Winkelmann; Summer R Gorder; Peter W Mason; Gregg N Milligan
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

9.  Valency and density matter: Deciphering impacts of immunogen structures on immune responses against a tumor associated carbohydrate antigen using synthetic glycopolymers.

Authors:  Qian Qin; Zhaojun Yin; Xuanjun Wu; Karen M Haas; Xuefei Huang
Journal:  Biomaterials       Date:  2016-06-02       Impact factor: 12.479

Review 10.  Synthetic Nanoparticles for Vaccines and Immunotherapy.

Authors:  Darrell J Irvine; Melissa C Hanson; Kavya Rakhra; Talar Tokatlian
Journal:  Chem Rev       Date:  2015-07-08       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.